CareLit · DOI-Nachweis · Pneumologie
Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials
DOI 10.1055/s-0035-1544834
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Pfeifer, V Cottin, H Taniguchi, L Richeldi, HR Collard, M Kaye, DM Hansell, Z Bailes, R Schlenker-Herceg, G Raghu
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The INPULSIS™ trials were two replicate randomized, placebo-controlled, 52-week Phase III trials that assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF. In both trials, nintedanib slowed disease progression by significantly reducing the annual rate of decline in forced vital capacity (FVC), the primary endpoint, compared with placebo. Methods: A post-hoc subgroup anal…
Zitieren
Zitierempfehlung
M Pfeifer, V Cottin, H Taniguchi, L Richeldi, HR Collard, M Kaye, DM Hansell, Z Bailes, R Schlenker-Herceg, G Raghu (2015) Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials. Pneumologie (02). https://doi.org/10.1055/s-0035-1544834
Mit CareLit weiterarbeiten